VSTM, US92337C2035

BTIG keeps its Buy rating for Verastem stock

Published on 10/07/2026 at 04:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 40.08 million versus USD 22.88 million expected. BTIG targets Verastem stock at USD 18.00 on October 5, 2026.

VSTM, US92337C2035, Illustration mit AI erstellt.

Verastem (ISIN US92337C2035) retains a Buy rating from BTIG Research, which maintained an USD 18.00 price target on October 5, 2026, according to MarketBeat. The rating leaves the upcoming clinical data readout as the central test for the companys cancer pipeline.

RAMP 201 data show measurable activity

Verastem announced new RAMP 201 analyses on October 2, 2026, covering avutometinib plus defactinib in recurrent low-grade serous ovarian cancer, as reported by WBOC. In the subgroup with KRAS, NRAS and BRAF all wild type, the combination produced an 18.00 percent confirmed objective response rate and median progression-free survival of 13.00 months.

The same October 2, 2026 analysis reported a weighted objective response rate of 38.70 percent with the combination versus 0.00 percent with conventional care in KRAS-mutated disease. That comparison gives the clinical story a measurable benchmark, although response data remain separate from commercial performance.

Revenue exceeded the second-quarter estimate

Verastem reported USD 40.08 million in revenue for the second quarter of 2026, versus an analyst estimate of USD 22.88 million, while its adjusted loss was USD 0.35 per share versus a USD 0.43 consensus loss, according to MarketBeat. The revenue comparison is partly shaped by USD 25.10 million in net product sales and a USD 15.00 million license payment, making the composition of the quarter important for investors assessing repeatability.

The companys cash and cash equivalents stood at USD 136.4 million on June 30, 2026, while operating cash flow was negative USD 43.9 million in the second quarter. Those figures put the clinical timetable alongside a clear financing consideration as Verastem advances multiple trials.

October 14 brings the next data test

Verastem scheduled an investor event for October 14, 2026, at 8:00 a.m. ET to present initial efficacy and updated safety data for VS-7375 across pancreatic, lung and colorectal cancers, according to the companys investor page. The program includes one Phase 1/2 trial and three registration-directed Phase 2 studies, so the readout spans several tumor types rather than a single indication.

Prior close stays the market anchor

Verastem had a prior close of EUR 7.01 at Lang & Schwarz on October 5, 2026. Its market capitalization was USD 681.0 million as of October 6, 2026, while the Nasdaq listing identifies the company under ticker VSTM. The further course of trading is shown by the continuously updated real-time quote of Verastem stock.